Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

What Happened: The legal spat stems from the federal 340B Drug Pricing Program, which provides discounted medications to ...

We see access to basic services (tied to potential US policy changes on drug pricing) as the next-biggest potential ESG ... We provide a platform for our authors to report on investments fairly, ...

Johnson & Johnson launched a legal challenge against a federal health agency blocking the company’s quest to tighten the way ...

Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of ...

Setrusumab receives Breakthrough Therapy designation from the FDACash of $80.5 million as of September 30, 2024, expected to fund operations into ...

BHG revealed its move in an open letter to Assertio stockholders, citing the board’s failure to address “fraud and misconduct ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call.

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Q3 2024 Earnings Call Transcript November 7, 2024 ClearPoint Neuro, Inc. misses on earnings expectations. Reported EPS is $-0 ...